Lyrica (pregabalin)
- Region
- 🇪🇺 EU
- Active substance
- pregabalin
- Company
- Viatris EESV
- Status
- Authorised
- Therapeutic area
- Epilepsy; Anxiety Disorders; Neuralgia
- EU approval
- Mon 05 Jul 2004
- Application
- EMEA/H/C/000546
- ATC
- N02BF02
- Official record
- www.ema.europa.eu
Indication
Neuropathic pain Lyrica is indicated for the treatment of peripheral and central neuropathic pain in adults. Epilepsy Lyrica is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation. Generalised anxiety disorder Lyrica is indicated for the treatment of generalised anxiety disorder (GAD) in adults.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Pregabalin Viatris (previously Pregabalin Mylan) Authorised · Viatris Limited
- 🇪🇺 Pregabalin Viatris Pharma (previously Pregabalin Pfizer) Authorised · Viatris Healthcare Limited
- 🇪🇺 Pregabalin Zentiva Authorised · Zentiva k.s.
- 🇪🇺 Pregabalin Sandoz Authorised · Sandoz GmbH
- 🇪🇺 Pregabalin Accord Authorised · Accord Healthcare S.L.U.
- 🇪🇺 Pregabalin Sandoz GmbH Withdrawn · Sandoz GmbH
- 🇪🇺 Pregabalin Zentiva k.s. Withdrawn · Zentiva k.s.
- 🇪🇺 Pregabalin Mylan Pharma Withdrawn · Mylan S.A.S.
Follow Lyrica
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.